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Ascitic Fluid “Humoral Tests of Malignancy” 
To the Editor: 
The recent paper by Jungst et al. (1) is another in a 
series of papers that propose a new ascitic fluid “humoral 
test of malignancy” (2, 3). The basic premise of these 
publications is that the ascitic fluid cytology is insensi- 
tive in detecting cancer as the cause of ascites formation. 
In general, cytologic analysis is said to detect only about 
two-thirds of patients with malignant ascites, as if all 
patients with malignant ascites should have peritoneal 
carcinomatosis (2, 3). However, in my experience, cytol- 
ogy has greater than 90% sensitivity in detecting peri- 
toneal carcinomatosis, but is negative in patients with 
massive liver metastases and resulting portal hyperten- 
sion-related ascites (Runyon, B. A. and Hoefs, J .  C., 
Hepatology 1985; 5:1000, Abstract). The problem is that 
a significant fraction of patients that are included in the 
series of patients with intraabdominal tumor have only 
massive liver metastases without peritoneal carcinoma- 
tosis. Patients who have only massive liver metastases 
do not have positive ascitic fluid cytologies. It is my 
impression that investigators have assumed that the vast 
majority of cancer patients who develop ascites have 
peritoneal carcinomatosis as the cause of ascites forma- 
tion. In fact, ascites caused by massive liver metastases 
is not rare. With careful investigation, massive liver 
metastases have been found to cause ascites in 26 to 33% 
of patients who have cancer and ascites; in general, 
patients have either peritoneal carcinomatosis or massive 
liver metastases, but not both (4; Runyon, B. A. and 
Hoefs, J. C. ,  Hepatology 1985; 51000, Abstract). It is the 
inclusion of patients with massive liver metastases in 
series of malignant ascites that leads to the 67% sensi- 
tivity value of cytology. Cytology is much more sensitive 
when it is applied to the appropriate subgroup of malig- 
nant ascites patients-the patients with peritoneal car- 
cinomatosis. 
Ascitic fluid caused by peritoneal carcinomatosis is 
markedly different than fluid caused by massive liver 
metastases. The former has a high protein concentration 
and low serum-ascites albumin concentration gradient 
(unless the patient also has cirrhosis), and the latter has 
a low protein concentration and a high gradient (5). The 
ascitic fluid of patients with massive liver metastases is 
so similar to that of cirrhotic ascites that it is possible 
that some patients with massive liver metastases might 
have been erroneously classified into the cirrhotic ascites 
category of some studies. Fibronectin concentration 
(mean f S.D.) in ascitic fluid caused by massive liver 
metastases-related ascites is 55 f 21 pg per ml compared 
to 123 & 45 pg per ml for peritoneal carcinomatosis; only 
20% of massive liver metastases-related ascites speci- 
mens have a fibronectin concentration greater than 75 
p g  per ml (6) ,  which is the proposed lower limit cut-off 
for malignancy (3). To analyze malignant ascites without 
subgrouping patients is to ignore the heterogeneity that 
is present in the series. 
Another problem with 2 of the 3 papers on “humoral 
tests for malignancy” (1, 2) is that they did not include 
a control group of noncirrhotic, nonmalignant ascites 
samples. In my study, the fibronectin concentration of 
“miscellaneous” samples (pancreatitis, heart failure, 
renal failure, etc.) overlapped essentially completely with 
that of the malignant ascites samples (including both 
subgroups), rendering the test useless in discriminating 
between miscellaneous and malignant samples (6). In my 
study of ascitic fluid cholesterol and triglycerides (ana- 
lyzed by Technicon Autoanalyzer), the overlap between 
groups was also excessive (see Figures 1 and 2). Although 
the cholesterol concentration of cirrhotic ascites samples 
(18 & 13 mg per dl) was significantly (p < 0.001) lower 
than that of peritoneal carcinomatosis samples (83 f 37 
mg per dl) and significantly (p < 0.02) lower than massive 
liver metastases samples (43 k 23 mg per dl), there was 
no difference between the cholesterol of miscellaneous 
samples (63 & 30 mg per dl) and that of either subgroup 
(or the aggregate) of malignant samples. There were no 
differences between any groups regarding ascitic fluid 
triglyceride concentration in my study. Tests that cannot 
discriminate between malignant samples and miscella- 
neous samples are of limited value, in my opinion. It is 
unrealistic to expect any one ascites test to detect all 
patients with malignant ascites just as it was unrealistic 
to expect the plasma fibronectin test to detect all patients 
with cancer (7). What we need are better definitions of 
subgroups of malignant ascites patients and stratifica- 
tion of data into subgroups. What we do not need are 
more ascitic fluid “humoral tests of malignancy.” 
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FIG. 1. Ascitic fluid cholesterol concentration in patients with sterile 
portal hypertension-related ascites (PHT) due to parenchymal liver 
disease, ascites due to peritoneal carcinomatosis (PCA), massive liver 
metastases (MLM) or miscellaneous causes ( M I X ) .  
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FIG. 2. Ascitic fluid triglyceride concentration in patients with portal 
hypertension-related ascites (PHT) due to parenchymal liver disease, 
ascites due to peritoneal carcinomatosis (PCA), massive liver metas- 
tases (MLM) or miscellaneous causes (MISC). 
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Reply: 
Runyon questioned the clinical usefulness of ascitic 
fluid cholesterol in the diagnosis of malignant ascites. 
He recommended a better definition of subgroups of 
malignant ascites patients and stratification of data into 
these subgroups. In the case of ascitic cytology, he re- 
ported a 90% sensitivity in detecting peritoneal carci- 
nomatosis but usually negative results in patients with 
massive liver metastases. We agree that the inclusion of 
patients with massive liver metastases in series of malig- 
nant ascites may have been one reason that the sensitiv- 
ity of ascitic fluid cytology was considerable lower in 
previous studies. In our study, it was our goal to discrim- 
inate ascites due to malignancies from ascites from non- 
malignant causes by cholesterol analysis. Regarding this 
major aim, the argument of Runyon seemed to be of 
limited relevance. 
As shown in Figure 1, all 23 patients with cirrhosis 
and portal hypertension had ascitic cholesterol concen- 
trations below the discrimination value of 48 mg per dl. 
These findings were supported by Runyon’s data. In 
comparison, only 4 from a total of 40 patients with 
malignant ascites (peritoneal carcinomatosis and mas- 
sive liver metastases) revealed an ascitic fluid cholesterol 
below 48 mg per dl, 2 from 25 patients with positive 
ascitic cytology and 2 from 15 patients with negative 
cytology (Figure 1). 
There is an overlap with cholesterol concentrations in 
ascites caused by heart failure and pancreatitis (miscel- 
laneous causes), but the prevalence of these miscella- 
neous causes of ascites is low in our hospital. We agree 
with Runyon that elevated ascitic cholesterol is not a 
specific sign of malignancy, but in our experience and 
with the rather high prevalence of malignant ascites in 
our hospital, the probability of an underlying malignant 
disease in patients with elevated ascitic cholesterol ex- 
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FIG. 1. Ascitic fluid cholesterol concentration in patients with sterile 
portal hypertension-related ascites (PHT) due to parenchymal liver 
disease, ascites due to peritoneal carcinomatosis (PCA), massive liver 
metastases (MLM) or miscellaneous causes (MISC). 
ceeds 90%. Of course, the simple cholesterol measure- 
ment cannot offer a definitive diagnosis but may be a 
useful hint for the further diagnostic procedures in such 
patients. 
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